PD25-03 TREATMENT WITH UGN-102 IN PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH DURATION OF RESPONSE DATA FROM THE PHASE 3 ENVISION TRIAL

The Journal of Urology 2026

View at publisher
Authors: Sandip M. Prasad, Nikola V. Mihaylov, Pencho Genov, Vasyl Terzi, William C. Huang, Michael J. Louie, Brent Burger, Andrew Meads, Mark Schoenberg
DOI: 10.1097/01.ju.0001191716.05440.37.03
Cited by: 1

Fields of Study & Subjects

Prostate Cancer Treatment and Research Bladder and Urothelial Cancer Treatments Lung Cancer Research Studies

Publication details

Journal / source
The Journal of Urology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
215
Issue
5S
Publication date
27 April 2026
Language
EN